Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
24 Cognitive Impairment Trials near Miami, FL
Power is an online platform that helps thousands of Cognitive Impairment patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerMetformin for Alzheimer's Disease
Miami, FloridaMAP will be a multisite phase II/III 1:1 randomized controlled trial (RCT) of long acting metformin (reduced mass Glucophage XR) vs. matching placebo in 326 men and women with early and late aMCI, without diabetes, not treated with metformin, overweight or obese, aged 55 years to 90 years. The RCT will last 18 months and have 4 visits: baseline, 6-months, 12-months, and 18-months. The RCT will be preceded by a screening phase followed by randomization and a titration period in which drug/placebo will be titrated from 500 mg a day (one tablet) to 2,000 mg a day (4 tablets), in increments of 500 mg (one tablet) every 10 days. Participants will remain in the RCT on the tolerated dose, and included in analyses on an intent to treat basis. We expect the attrition rate to be 10%/year. Neuropsychological battery, clinical interviews, physical exam, and phlebotomy will be conducted at baseline and every 6 months. Brain MRI will be conducted in approximately half of the participants (186) twice, at baseline, and after the last study visit at month 18. We will also conduct brain amyloid Positron Emission Tomography (PET) using 18F-Florbetaben, and tau PET using 18F-MK6240 in half of the participants at baseline and end of the RCT.
The primary clinical outcome of the study will be changes in the Free and Cued Selective Reminding Test. The secondary endpoints are 1) changes in global cognitive performance, measured with the Alzheimer's Disease Cooperative Study Preclinical Alzheimer Cognitive Composite (ADCS-PACC); 2) changes in neurodegeneration, ascertained as cortical thickness in areas affected by AD on brain MRI; 3) changes in cerebrovascular disease, ascertained as white matter hyperintensities (WMH) volume on brain MRI; 4) Changes in whole brain amyloid ß (Aß) SUVR and in incident amyloid positivity; 5) Changes in tau SUVR in a composite brain region comprising medial and inferolateral temporal cortex; 6) Changes in plasma AD biomarkers.
The data coordinating center and Imaging Core is located at John Hopkins University. The PET coordinating center is located at UC-Berkeley. The Clinical Coordinating and Monitoring Center and the central laboratory will be located at Columbia. The Research pharmacy function will be shared by the University of Rochester, which will dispense randomization kits, and the University of Iowa, which will receive bulk metformin and identical matching placebo from EMD Serono.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2, 3
Age:55 - 90
Sex:All
326 Participants Needed
Semaglutide for Early Alzheimer's Disease
Miami, FloridaThis study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.
Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which treatment participants get is decided by an equal chance.
The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans. At 10 of the clinic visits participants will have blood samples taken.
Participants must have a study partner, who is willing to take part in the study.
Women cannot take part if pregnant, breastfeeding or plan to become pregnant during the study period.
A cerebrospinal fluid (CSF) sub-study will be performed as a part of the study. The sub-study will be performed on a selection of sites based on their experience with CSF sampling and willingness to participate in this sub-study. The endpoints related to this sub-study are exploratory only.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:55 - 85
Sex:All
1840 Participants Needed
Nicotine Patch for Mild Cognitive Impairment
Miami, FloridaThe purpose of the study is to see if daily transdermal nicotine is able to produce a significant cognitive, clinical and functional improvement in participants with MCI. Neuronal nicotinic receptors have long been known to play a critical role in memory function in preclinical studies, with nicotine improving attention, learning, and memory function.
The study will enroll 380 participants for a 2 year period. Participants will be randomized (50:50) to either the transdermal nicotine, beginning at 7mg/day, and increasing to 21mg/day, or placebo skin patch.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:55 - 90
Sex:All
380 Participants Needed
JNJ-63733657 for Alzheimer's Disease
Miami, FloridaThis trial is testing a new drug called JNJ-63733657 to see if it can help slow down the worsening of symptoms in patients with Alzheimer's disease. The goal is to see if the drug can help maintain brain function and daily living skills better.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:55 - 80
Sex:All
523 Participants Needed
Atorvastatin for Preventing Dementia
Miami, FloridaPREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the benefit of statins for reducing the primary composite of death, dementia, and persistent disability and secondary composites including mild cognitive impairment (MCI) and cardiovascular events.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:75+
Sex:All
Key Eligibility Criteria
Disqualifiers:Cardiovascular Disease, Dementia, ADL Dependence, Others
Must Not Be Taking:Statins
20000 Participants Needed
BMS-986446 for Early Alzheimer's Disease
Miami, FloridaThis trial is testing a new medication called BMS-986446 in people with early Alzheimer's disease. The medication is designed to target harmful proteins in the brain to slow down the disease. Researchers are checking if it works well and is safe for patients.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:50 - 80
Sex:All
Key Eligibility Criteria
Disqualifiers:Other Cognitive Conditions, MRI Contraindications, Others
475 Participants Needed
Piromelatine for Alzheimer's Disease
Miami, FloridaThis trial tests piromelatine, a pill taken before bed, in people with mild Alzheimer's who lack a specific genetic variation. The goal is to see if it can improve brain function and slow down dementia progression.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2, 3
Age:60 - 85
Sex:All
225 Participants Needed
Sensory Stimulation for Alzheimer's Disease
Miami, FloridaThis trial is testing a device that uses light and sound to help patients with mild to moderate Alzheimer's disease. The goal is to see if this sensory stimulation can slow down the progression of the disease by improving brain function. This therapy has shown potential for application in the treatment of Alzheimer's disease.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:50 - 90
Sex:All
Key Eligibility Criteria
Disqualifiers:Seizure Disorder, Schizophrenia, Heart Disease, Others
Must Be Taking:Acetylcholinesterase Inhibitors
600 Participants Needed
Xanamem for Alzheimer's Disease
Miami, FloridaXanamem® is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD).
This XanaMIA Phase 2b/3 study is to investigate the safety, tolerability, and efficacy of Xanamem in in mild or moderate dementia due to AD. Trial participants will be randomized to either receive 10mg of Xanamem once daily or a placebo for 36 weeks at a 1:1 ratio in a double-blinded fashion.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Non-AD Dementia, Major Mental Illness, Diabetes, Others
Must Be Taking:Symptomatic AD Medications
220 Participants Needed
Ca-Mg Butyrate for Gulf War Syndrome
Miami, FloridaThe primary objective of this clinical trial is to determine if treatment with Butyrate formulation that consists of butyric acid as calcium and magnesium derivatives (Ca-Mg Butyrate) improves the physical function of men and women Veterans suffering from Gulf War Illness (GWI). The primary outcome measure is a change from baseline on the Short Form Health Survey 36-item (VSF-36), with respect to physical functioning and symptoms. The secondary outcome will focus on the drug's role in (a) restoring gut microbiome and virome, (b) decreasing gastrointestinal disturbances (constipation, diarrhea, pain), (c) decreasing chronic fatigue, (d) decreasing systemic inflammation, and (e) a decrease in cognitive deficits.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:40 - 70
Sex:All
Key Eligibility Criteria
Disqualifiers:Schizophrenia, Bipolar, Organ Failure, Others
Must Not Be Taking:Steroids, Antibiotics, Immunosuppressives, Others
120 Participants Needed
Donanemab for Early Alzheimer's Disease
Miami, FloridaThis trial is testing donanemab, a drug for early Alzheimer's disease. It targets people with early symptoms and specific brain changes. The drug helps remove harmful proteins from the brain, potentially slowing down or improving symptoms.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:60 - 85
Sex:All
1736 Participants Needed
ACU193 for Early Alzheimer's Disease
Coral Gables, FloridaThe primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:50 - 90
Sex:All
540 Participants Needed
Benfotiamine for Alzheimer's Disease
Miami, FloridaThe purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine which may delay or slow the progression of the symptoms of early Alzheimer's disease.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:50 - 89
Sex:All
Key Eligibility Criteria
Disqualifiers:Neurological Disorders, Diabetes, Cancer, Others
Must Be Taking:Acetylcholinesterase Inhibitors, Memantine
406 Participants Needed
LY3372689 for Alzheimer's Disease
Miami, FloridaThis trial is testing a new drug, LY3372689, on people with early symptoms of Alzheimer's Disease to see if it is safe and how it affects their symptoms.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:60 - 85
Sex:All
330 Participants Needed
Polypill for Alzheimer's Disease
Miami, FloridaThe goal of this clinical trial is to assess the clinical response to a drug combination type of polypill in patients with AD after 180 days of treatment. The anticipated study population are males and females aged 50-85 years with mild to severe Alzheimer's Disease. The duration of individual patient participation will be approximately 224 Days: up to 14 days for Screening, 180 days for study drug administration, and a final follow-up visit at 210 days. The planned study duration is 12-18 months from Screening of the first patient until the last follow-up of the last patients.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:50 - 85
Sex:All
Key Eligibility Criteria
Disqualifiers:Neurological Disorders, Liver Disease, Schizophrenia, Others
Must Be Taking:Anticholinesterase, Memantine, Herbal
206 Participants Needed
Remternetug for Alzheimer's Disease
Miami, FloridaThis trial tests remternetug, a drug given by injection or IV, in people with early Alzheimer's disease. It aims to find out if the drug is safe and can help improve symptoms or slow down the disease.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:60 - 85
Sex:All
1667 Participants Needed
Yoga Training for Cognitive Impairment
Coral Gables, FloridaThis study will compare the impact of a novel high-speed, cued yoga program to a standard yoga program on retinal microvasculature, cognition and neuromuscular function.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:60 - 90
Sex:All
Key Eligibility Criteria
Disqualifiers:Cardiovascular, Neuromuscular, Cerebrovascular, HIV, Others
50 Participants Needed
ALTO-101 for Schizophrenia
Hollywood, FloridaThis is a Phase 2, double-blind, placebo-controlled, two-way crossover study to compare the efficacy of ALTO-101T versus placebo in change in electroencephalogram (EEG) cognitive processing markers and measures of cognition.
Additional goals are to assess pharmacokinetic (PK), safety, and tolerability of the recently developed ALTO-101T transdermal delivery system (TDS) formulation in a patient population.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:21 - 55
Sex:All
Key Eligibility Criteria
Disqualifiers:Unstable Condition, Bipolar, Dementia, Others
Must Be Taking:Antipsychotics
82 Participants Needed
Precision Medicine for Dementia
Hollywood, FloridaThe goal of this clinical trial is to compare a precision medicine approach to the standard-of-care for people with mild cognitive impairment or early-stage dementia. Precision medicine approach starts with the completion of many tests and then the study doctor uses the test results to carefully prepare a treatment plan that is best for the individual person to help treat many of the underlying causes of mild cognitive impairment or early-stage dementia.
The main question the study aims to answer is:
• Does the precision medicine approach improve memory (cognitive function) better than the current standard-of-care treatment in people with mild cognitive impairment or early-stage dementia during a 9-month treatment period? This is a randomized clinical trial which means that a group of people that meet the study requirements will be assigned at random or by chance (like toss of a coin) to receive either the precision medicine treatment or the current gold standard (standard-of-care). People assigned to the precision medicine group will receive precision medicine for 9-months while those assigned to the standard-of-care group will follow that approach for 9-months, followed by an opportunity to receive up to six months of precision medicine, if desired.
Participants will be asked to:
* Have their blood drawn for extensive lab testing and collect urine and stool samples as well
* Carefully follow instructions received from their study doctor and study team
* Make lifestyle changes as prescribed by the study doctor and study team based on your precision medicine program
* Take supplements and medications prescribed by the study doctor.
* Once officially in the study (after meeting study entry or screening requirements), participate in ten (10) monthly visits with the study doctor, and other members of the study team as scheduled.
* Complete cognitive tests at scheduled visits during the study
* Have a study partner with you during visits and to help support you on the program Researchers will compare test results between the two study groups to see if the precision medicine approach improves those tests results over the time of the study, resulting in the improvement of cognition over a 9-month treatment period.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:45 - 76
Sex:All
Key Eligibility Criteria
Disqualifiers:Uncontrolled Illness, Type 1 Diabetes, Cancer, Others
Must Be Taking:Aricept
72 Participants Needed
Cognitive Training for Breast Cancer Survivors
Fort Lauderdale, FloridaThis Phase III trial will examine the efficacy of computerized cognitive training methods on perceived cognitive impairment in breast cancer survivors.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 100
Sex:All
Key Eligibility Criteria
Disqualifiers:Metastatic Disease, Other Cancer, CNS Radiation, Stroke, Substance Abuse, Others
386 Participants Needed
Baricitinib for Alzheimer's & ALS
Fort Lauderdale, FloridaThis trial tests baricitinib, a pill taken daily, in people with early signs of Alzheimer's or ALS, or those at risk. The goal is to see if it can reduce harmful inflammation in the brain. Participants will take the medication for several months to check if it reaches the brain and lowers inflammation. Baricitinib is used for the treatment of rheumatoid arthritis and has shown promising preliminary data for moderate-to-severe atopic dermatitis.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18 - 90
Sex:All
20 Participants Needed
Sensory Stimulation for Alzheimer's Disease
Pompano Beach, FloridaThis is an open-label extension for a multicenter, randomized, double-blind, sham-controlled, adaptive design pivotal study.
Participants who complete the Hope Study (CA-0011) will be eligible to consent for screening to enroll in the OLE Hope Study (CA-0015). All participants will be treated with an Active Sensory Stimulation System (GS120) for 60 minutes daily for up to 12 months. There will be no Sham treatment group or randomization involved in this study.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Unphased
Age:50 - 92
Sex:All
402 Participants Needed
Stem Cell Therapy for Neurological Disorders
Coral Springs, FloridaThis is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http://mdstemcells.com/nest/
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Medically Unstable, Others
500 Participants Needed
Leuprolide for Alzheimer's Disease
Boca Raton, FloridaThe LUCINDA Trial is a three-site, phase II, randomized, double-blind, placebo-controlled study of leuprolide acetate (Eligard) in women with Mild Cognitive Impairment or Alzheimer's Disease taking a stable dose of a cholinesterase inhibitor medication like donepezil. Its objective is to assess the efficacy of a 48-week regimen of leuprolide (22.5 mg per 12 weeks) compared to placebo on cognitive function, global function and plasma and neuroimaging biomarkers.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:60+
Sex:Female
Key Eligibility Criteria
Disqualifiers:Schizophrenia, Epilepsy, Parkinson's, Others
Must Be Taking:Cholinesterase Inhibitors
180 Participants Needed
Page 1 of 1+
Learn More About Power
My name is Bask, and I helped to start the company here. We started Power when my Dad was diagnosed with multiple myeloma, and I needed a better way to understand how he could access the most promising immunotherapy for his illness.
Bask GillCEO at Power
Frequently Asked Questions
How much do Cognitive Impairment clinical trials in Miami, FL pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Cognitive Impairment clinical trials in Miami, FL work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Cognitive Impairment trials in Miami, FL 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Miami, FL for Cognitive Impairment is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Miami, FL several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Cognitive Impairment medical study in Miami, FL ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Cognitive Impairment clinical trials in Miami, FL ?
Most recently, we added Polypill for Alzheimer's Disease, ALTO-101 for Schizophrenia and Xanamem for Alzheimer's Disease to the Power online platform.